SIVMAC239 IMMUNOGENIC PLASMIDS, RECOMBINANT ADENOVIRAL VECTORS, AND IMMUNIZATION PROTOCOL USING THE SAME THAT REDUCE VIRAL LOADS AFTER MUCOSAL SIVMAC239 INFECTION

摘要

A DNA vaccine composition and a recombinant adenovirus vaccine composition using an SIVmac239/rhesus macaque model are provided to show excellent AIDS virus infection prophylactic and therapeutic effect when being applied to a priming-boosting technique, thereby being used as a novel agent for preventing and treating the AIDS. A priming vaccine composition for preventing or treating AIDS comprises: (a) an immunogenic plasmid including an SIV Gag gene and an Env gene; and (b) an immunogenic plasmid including a gene codon-optimized by nef-tat-vpx-vif-tat. A boosting vaccine composition for preventing or treating AIDS comprises: (a) a recombinant adenovirus including an SIV Gag gene and an Env gene; and (b) a recombinant adenovirus including an sVif-Nef gene and an sTat-Vpx gene. A vaccine kit for preventing or treating AIDS comprises the priming vaccine composition and the boosting vaccine composition. Further, the priming vaccine composition for preventing or treating AIDS additionally comprises a PLGA(poly lactic-co-glycolic acid)-Y peptide.